- Home
- NEOV vs SGMT Comparison
NEOV vs SGMT Comparison
Compare NEOV & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NEOV | SGMT |
|---|---|---|
| Founded | 2018 | 2006 |
| Country | United States | United States |
| Employees | 17 | N/A |
| Industry | Industrial Machinery/Components | |
| Sector | Miscellaneous | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 145.6M | 169.4M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | NEOV | SGMT |
|---|---|---|
| Price | $2.81 | $8.48 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | N/A | ★ $26.38 |
| AVG Volume (30 Days) | 410.3K | ★ 2.2M |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,000,000.00 |
| Revenue This Year | $150.56 | N/A |
| Revenue Next Year | $5.31 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.65 | $3.15 |
| 52 Week High | $7.13 | $11.41 |
Technical Indicators
Market Signals| Indicator | NEOV | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 40.93 | 74.09 |
| Support Level | $2.80 | $7.99 |
| Resistance Level | $3.35 | $9.02 |
| Average True Range (ATR) | 0.22 | 0.56 |
| MACD | -0.00 | 0.24 |
| Stochastic Oscillator | 22.86 | 74.28 |
Price Performance
Historical ComparisonAbout NEOV NeoVolta Inc.
NeoVolta Inc is engaged in designing, manufacturing and sale of high end Energy Storage System which can store and use solar energy via batteries and an inverter at a residential site. Its market place includes solar industry, installers, new construction homebuilders, home remodelers and homeowners.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.